198 related articles for article (PubMed ID: 24405719)
1. Cost-effectiveness of tenofovir gel in urban South Africa: model projections of HIV impact and threshold product prices.
Terris-Prestholt F; Foss AM; Cox AP; Heise L; Meyer-Rath G; Delany-Moretlwe S; Mertenskoetter T; Rees H; Vickerman P; Watts CH
BMC Infect Dis; 2014 Jan; 14():14. PubMed ID: 24405719
[TBL] [Abstract][Full Text] [Related]
2. Epidemiological impact of tenofovir gel on the HIV epidemic in South Africa.
Williams BG; Abdool Karim SS; Karim QA; Gouws E
J Acquir Immune Defic Syndr; 2011 Oct; 58(2):207-10. PubMed ID: 21654503
[TBL] [Abstract][Full Text] [Related]
3. The cost-effectiveness of pre-exposure prophylaxis for HIV infection in South African women.
Walensky RP; Park JE; Wood R; Freedberg KA; Scott CA; Bekker LG; Losina E; Mayer KH; Seage GR; Paltiel AD
Clin Infect Dis; 2012 May; 54(10):1504-13. PubMed ID: 22474224
[TBL] [Abstract][Full Text] [Related]
4. Tenofovir Gel for the Prevention of Herpes Simplex Virus Type 2 Infection.
Abdool Karim SS; Abdool Karim Q; Kharsany AB; Baxter C; Grobler AC; Werner L; Kashuba A; Mansoor LE; Samsunder N; Mindel A; Gengiah TN;
N Engl J Med; 2015 Aug; 373(6):530-9. PubMed ID: 26244306
[TBL] [Abstract][Full Text] [Related]
5. Relative cost-effectiveness of long-acting injectable cabotegravir versus oral pre-exposure prophylaxis in South Africa based on the HPTN 083 and HPTN 084 trials: a modelled economic evaluation and threshold analysis.
Jamieson L; Johnson LF; Nichols BE; Delany-Moretlwe S; Hosseinipour MC; Russell C; Meyer-Rath G
Lancet HIV; 2022 Dec; 9(12):e857-e867. PubMed ID: 36356603
[TBL] [Abstract][Full Text] [Related]
6. Estimating the cost-effectiveness of pre-exposure prophylaxis to reduce HIV-1 and HSV-2 incidence in HIV-serodiscordant couples in South Africa.
Jewell BL; Cremin I; Pickles M; Celum C; Baeten JM; Delany-Moretlwe S; Hallett TB
PLoS One; 2015; 10(1):e0115511. PubMed ID: 25616135
[TBL] [Abstract][Full Text] [Related]
7. Portfolios of biomedical HIV interventions in South Africa: a cost-effectiveness analysis.
Long EF; Stavert RR
J Gen Intern Med; 2013 Oct; 28(10):1294-301. PubMed ID: 23588668
[TBL] [Abstract][Full Text] [Related]
8. The cost-effectiveness of multi-purpose HIV and pregnancy prevention technologies in South Africa.
Quaife M; Terris-Prestholt F; Eakle R; Cabrera Escobar MA; Kilbourne-Brook M; Mvundura M; Meyer-Rath G; Delany-Moretlwe S; Vickerman P
J Int AIDS Soc; 2018 Mar; 21(3):. PubMed ID: 29537654
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women.
Abdool Karim Q; Abdool Karim SS; Frohlich JA; Grobler AC; Baxter C; Mansoor LE; Kharsany AB; Sibeko S; Mlisana KP; Omar Z; Gengiah TN; Maarschalk S; Arulappan N; Mlotshwa M; Morris L; Taylor D;
Science; 2010 Sep; 329(5996):1168-74. PubMed ID: 20643915
[TBL] [Abstract][Full Text] [Related]
10. Topical microbicides for prevention of sexually transmitted infections.
Obiero J; Mwethera PG; Wiysonge CS
Cochrane Database Syst Rev; 2012 Jun; (6):CD007961. PubMed ID: 22696373
[TBL] [Abstract][Full Text] [Related]
11. Cost and cost-effectiveness of switching from stavudine to tenofovir in first-line antiretroviral regimens in South Africa.
Rosen S; Long L; Fox M; Sanne I
J Acquir Immune Defic Syndr; 2008 Jul; 48(3):334-44. PubMed ID: 18545151
[TBL] [Abstract][Full Text] [Related]
12. Assessing the implementation effectiveness and safety of 1% tenofovir gel provision through family planning services in KwaZulu-Natal, South Africa: study protocol for an open-label randomized controlled trial.
Mansoor LE; Abdool Karim Q; Mngadi KT; Dlamini S; Montague C; Nkomonde N; Mvandaba N; Baxter C; Gengiah TN; Samsunder N; Dawood H; Grobler A; Frohlich JA; Abdool Karim SS
Trials; 2014 Dec; 15():496. PubMed ID: 25527071
[TBL] [Abstract][Full Text] [Related]
13. National and provincial estimated costs and cost effectiveness of a programme to reduce mother-to-child HIV transmission in South Africa.
Wilkinson D; Floyd K; Gilks CF
S Afr Med J; 2000 Aug; 90(8):794-8. PubMed ID: 11022629
[TBL] [Abstract][Full Text] [Related]
14. Cost and cost-effectiveness of a universal HIV testing and treatment intervention in Zambia and South Africa: evidence and projections from the HPTN 071 (PopART) trial.
Thomas R; Probert WJM; Sauter R; Mwenge L; Singh S; Kanema S; Vanqa N; Harper A; Burger R; Cori A; Pickles M; Bell-Mandla N; Yang B; Bwalya J; Phiri M; Shanaube K; Floyd S; Donnell D; Bock P; Ayles H; Fidler S; Hayes RJ; Fraser C; Hauck K;
Lancet Glob Health; 2021 May; 9(5):e668-e680. PubMed ID: 33721566
[TBL] [Abstract][Full Text] [Related]
15. Recruitment of high risk women for HIV prevention trials: baseline HIV prevalence and sexual behavior in the CAPRISA 004 tenofovir gel trial.
Karim QA; Kharsany AB; Frohlich JA; Baxter C; Yende N; Mansoor LE; Mlisana KP; Maarschalk S; Arulappan N; Grobler A; Sibeko S; Omar Z; Gengiah TN; Mlotshwa M; Samsunder N; Karim SS
Trials; 2011 Mar; 12():67. PubMed ID: 21385354
[TBL] [Abstract][Full Text] [Related]
16. Cost effectiveness of single-dose nevirapine regimen for mothers and babies to decrease vertical HIV-1 transmission in sub-Saharan Africa.
Marseille E; Kahn JG; Mmiro F; Guay L; Musoke P; Fowler MG; Jackson JB
Lancet; 1999 Sep; 354(9181):803-9. PubMed ID: 10485721
[TBL] [Abstract][Full Text] [Related]
17. Attaining realistic and substantial reductions in HIV incidence: model projections of combining microbicide and male circumcision interventions in rural Uganda.
Cox AP; Foss AM; Shafer LA; Nsubuga RN; Vickerman P; Hayes RJ; Watts C; White RG
Sex Transm Infect; 2011 Dec; 87(7):635-9. PubMed ID: 21768615
[TBL] [Abstract][Full Text] [Related]
18. The price of tenofovir-emtricitabine undermines the cost-effectiveness and advancement of pre-exposure prophylaxis.
Keller SB; Smith DM
AIDS; 2011 Nov; 25(18):2308-10. PubMed ID: 22067201
[No Abstract] [Full Text] [Related]
19. HIV preexposure prophylaxis in the United States: impact on lifetime infection risk, clinical outcomes, and cost-effectiveness.
Paltiel AD; Freedberg KA; Scott CA; Schackman BR; Losina E; Wang B; Seage GR; Sloan CE; Sax PE; Walensky RP
Clin Infect Dis; 2009 Mar; 48(6):806-15. PubMed ID: 19193111
[TBL] [Abstract][Full Text] [Related]
20. Innate immune activation enhances hiv acquisition in women, diminishing the effectiveness of tenofovir microbicide gel.
Naranbhai V; Abdool Karim SS; Altfeld M; Samsunder N; Durgiah R; Sibeko S; Abdool Karim Q; Carr WH;
J Infect Dis; 2012 Oct; 206(7):993-1001. PubMed ID: 22829639
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
